Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-01-08 @ 12:08 PM
Study NCT ID:
NCT00623233
Status:
COMPLETED
Last Update Posted:
2012-01-09
First Post:
2008-02-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
11649
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |